Osteopontin level correlates negatively with tumor shrinkage in neoadjuvant chemoradiation of locally advanced rectal cancer

Mirna Primasari, Soehartati A Gondhowiardjo, DiahRini Handjari, Sahat Matondang, Adang Bachtiar Kantaatmadja

Abstract


Background and Purpose: Neoadjuvant chemoradiation (CRT) is the mainstay treatment for locally advanced rectal carcinoma. However, the response is varied due to many factors, including tissue hypoxia. Osteopontin (OPN) is an emerging endogen hypoxic marker with significant correlation towards tumor pO2, also a more accurate chronic hypoxic marker compared to carbonic anhydrase IX (CAIX), glucose transporter 1 (GLUT1), and lactate dehydrogenase A (LDHA); but as far as we know there is no research that measured OPN quantity in rectal cancer tissue and correlated it with tumor shrinkage response in neoadjuvant CRT. Materials and Method: Fourteen patients that met the inclusion and exclusion criteria were analyzed retrospectively. Imaging was evaluated for tumor shrinkage percentage and categorized based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. OPN level quantitative results from rectal cancer tissue were obtained using ELISA method. Results: The mean OPN concentration was 0.568 ± 0.26 ng/mL. There was a significant strong negative correlation (= −0.630, = 0.016) between the OPN level and tumor shrinkage. OPN cut off value of ≥0.538 ng/mL predicted non-responsiveness of tumor shrinkage in neoadjuvant CRT with 100% sensitivity and 81.8% specificity. Conclusion: Hypoxia occurred in locally advanced rectal carcinoma patients. Higher level of OPN correlates negatively with tumor shrinkage, proved worse response of CRT given.

Keywords


rectal cancer; osteopontin; hypoxia; neoadjuvant chemoradiation

Full Text:

PDF

References


Garajová I, Di Girolamo S, de Rosa F, et al. Neoadjuvant treatment in rectal cancer: actual status. Chemother Res Pract. 2011:839742. doi:10.1155/2011/839742

National Comprehensive Cancer Network. NCCN Guidelines-Rectal Cancer. 2015;version 3:REC – 5.

Harrison L, Blackwell K. Hypoxia and Anemia : Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy ? Oncologist. 2004;9(suppl 5):31–40. doi:10.1634/theoncologist.9-90005-31

Zeng M, Kikuchi H, Pino MS, et al. Hypoxia Activates the K-Ras Proto-Oncogene to Stimulate Angiogenesis and Inhibit Apoptosis in Colon Cancer Cells. 2010;5(6).

Yaromina A, Krause M, Baumann M. Individualization of cancer treatment from radiotherapy perspective. Mol Oncol. Elsevier B.V; 2012;6(2):211–21. doi:10.1016/j.molonc.2012.01.007

Etiz D, Ataizi FC, Bayman E, et al. Prognostic Value of Osteopontin in Patients Treated with Primary Radiotherapy for Head and Neck Cancer. Asian Pacific J Cancer Prev. 2013 Sep ;14(9):5175. doi:10.7314/APJCP.2013.14.9.5175

Sase SP, Ganu JV, Nagane N. Osteopontin: A Novel Protein Molecule. Indian Medical Gazette. 2012; 62-6

Youssef NS, Osman WM. Relationship between osteopontin and β-catenin immunohistochemical expression and prognostic parameters of colorectal carcinoma. Int J Clin Exp Pathol. 2015;8(2):1503.

Li J, Yang GZ, Zhu ZM, et al. Osteopontin is overexpressed in colorectal carcinoma and is correlated with p53 by immunohistochemistry. Exp Ther Med. 2012 ;3(4):621-624.

Rohde F et al. Expression of osteopontin, a target gene of de-regulated Wnt signaling predicts survival in colon cancer. Int J. Cancer. 2007;121(8):1717-23.

Rodrigues LR, Teixeira J A, Schmitt FL, et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1087. doi:10.1158/1055-9965.EPI-06-1008

Fedarko NS, Jain A, Karadag A, et al. Elevated Serum Bone Sialoprotein and Osteopontin in Colon , Breast , Prostate , and Lung Cancer Elevated Serum Bone Sialoprotein and Osteopontin in Colon,. 2001;7(December):4060–6.

Solberg TD, Nearman J, Mullins J, et al. Correlation Between Tumor Growth Delay and Expression of Cancer and Host VEGF, VEGFR2, and Osteopontin in Response to Radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(3):918. doi:10.1016/j.ijrobp.2008.06.1925

Zhu Y, Denhardt DT, Cao H, et al. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras -activated enhancer. Oncogene. 2005;24:6555. doi:10.1038/sj.onc.1208800

Weber GF. The cancer biomarker osteopontin: Combination with other markers. Cancer Genomics and Proteomics. 2011;8(6):263.

Vaupel P, Harrison L. Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response. Oncologist. 2004;9(suppl 5):4. doi:10.1634/theoncologist.9-90005-4




DOI: http://dx.doi.org/10.30564/amor.v1i1.10

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Mirna Primasari, Soehartati A Gondhowiardjo, DiahRini Handjari, Sahat Matondang, Adang Bachtiar Kantaatmadja

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.